Discussion on the duration of response following HBsAg clearance in patients with chronic hepatitis B treated with PegIFNα-2b
Patients with chronic hepatitis B treated with PegIFNα-2b demonstrated favorable long-term persistence of HBsAg clearance. However, there remains a risk of HBsAg reversion after treatment cessation, predominantly within the first 48 weeks. HBsAg sustained response (HSR) at 48 weeks post-treatment is a critical follow-up time point for CHB patients post-HBsAg clearance, with HSR at 72 weeks potentially representing an ideal follow-up timeframe, while HSR at 120 weeks may serve as a marker for extended follow-up.
Authors
- Qin Du
- Fenghui Li (ORCID: https://orcid.org/0000-0003-2096-7908)
- Baiguo Xu (ORCID: https://orcid.org/0000-0002-0269-5155)
- Fei Yan (ORCID: https://orcid.org/0000-0003-4874-9582)
- Fei Tang (ORCID: https://orcid.org/0000-0003-1475-5028)
- Jing Chen (ORCID: https://orcid.org/0000-0002-3145-8220)
- Qing Ye (ORCID: https://orcid.org/0009-0004-5439-1892)
- Fang Wang (ORCID: https://orcid.org/0000-0002-9715-1838)
- Lei Liu (ORCID: https://orcid.org/0000-0001-6290-8602)
- Jing Liang (ORCID: https://orcid.org/0000-0003-0811-0223)
- Huiling Xiang (ORCID: https://orcid.org/0000-0001-5734-4080)
- Weili Yin
- Tao Wang (ORCID: https://orcid.org/0009-0003-1825-0163)
Institutions
- Tianjin Third Central Hospital (CN)
- Tianjin Medical University (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-04-08
- DOI
- https://doi.org/10.3389/fimmu.2025.1518048
- Primary Topic
- Hepatitis B Virus Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00